The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Hanmi Pharmaceutical's efpeglenatide is emerging as a serious contender in the GLP-1 obesity drug market, targeting the same patients who currently use Wegovy and Mounjaro. Here's what the emerging data suggests, what questions remain, and how to think about your own treatment options as new competitors arrive.
Rosie O'Donnell recently opened up about her exact Mounjaro dosage and her surprisingly smooth experience with the medication. Her story raises important questions about tirzepatide dosing, side effect management, and what patients can realistically expect. Here's how to make sense of her experience alongside the clinical evidence.
A new Medicare program is poised to significantly expand access to GLP-1 medications like semaglutide and tirzepatide for older Americans. Here's what beneficiaries need to know about eligibility, potential savings, and how to navigate the changes with their doctor.
Millions of people qualify for GLP-1 medications on paper, but a growing number are hitting roadblocks when they try to actually get them. From insurance denials to pharmacy shortages and prior authorization battles, here is what is standing between patients and their prescriptions, and what you can do about it.
Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit against a US competitor over advertising claims the company says are false and misleading. For patients comparing GLP-1 medications, this legal battle raises important questions about how drug ads shape treatment decisions. Here's what you need to know.
Novo Nordisk has filed a lawsuit against Eli Lilly, claiming the company runs deceptive advertising for its GLP-1 medications. For patients comparing semaglutide and tirzepatide options, this legal battle raises real questions about how drug makers market weight loss treatments and what you should actually trust when making a medication decision.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company ran misleading advertising around its GLP-1 medications. For patients comparing semaglutide and tirzepatide options, here is what this legal fight actually means for your treatment decisions and costs.
Millions of Americans who qualify for GLP-1 medications like semaglutide and tirzepatide are being turned away by their insurance plans due to high drug costs. This article breaks down why coverage gaps exist, what it costs to pay out of pocket, and the real options available to help you afford treatment.
.avif)
